文献速递消化道肿瘤放疗放疗物理与技术

既往常规分割放疗后局部复发胰腺腺癌的立体定向体部放疗再程照射

Reirradiation with stereotactic body radiation therapy after prior conventional fractionation radiation for locally recurrent pancreatic adenocarcinoma.
PubMed 文献 · Adv Radiat Oncol · 2017-01-18

本研究回顾性分析了23例既往接受常规分割放疗后局部复发的胰腺腺癌患者,采用立体定向体部放疗(SBRT)再程照射。中位随访28个月,再程照射后中位总生存8.5个月,局部失败累积发生率19%,远处进展累积发生率64%,26.1%患者出现2-3级胃肠道毒性,多分次方案毒性更低。

要点

  • SBRT再程照射局部复发胰腺癌可行,局部控制率较好。
  • 再程照射后中位总生存8.5个月,局部失败累积发生率19%。
  • 2-3级胃肠道毒性26.1%,多分次方案毒性更低。

核心结论

  • SBRT用于既往常规分割放疗后局部复发胰腺腺癌的再程照射是可行选择,局部控制好且毒性可接受,尤其多分次方案。

研究设计与样本

  • 回顾性研究,纳入本机构23例既往接受常规分割放疗后局部复发胰腺腺癌并接受SBRT再程照射的患者。

主要发现

  • 再程照射后中位总生存8.5个月(范围1个月至未达到),自诊断起中位总生存27.5个月(范围10-77个月)。
  • 末次随访局部失败累积发生率19%,远处进展累积发生率64%,区域失败累积发生率14%。
  • 再程照射后6例(26.1%)发生2-3级胃肠道毒性,其中4例发生在单次25 Gy SBRT组。

关键数值与推荐

  • 既往常规分割放疗中位剂量50.4 Gy(范围30-60 Gy)。
  • 9例(39.1%)接受单次25 Gy SBRT,14例(60.8%)接受5分次SBRT中位剂量25 Gy(范围20-33 Gy)。
  • 中位计划靶体积46 cm3(范围14-89 cm3),中位随访28个月(范围9-77个月)。

临床怎么用

  • 对既往常规分割放疗后局部复发胰腺腺癌可考虑SBRT再程照射,优先选择多分次方案以降低胃肠道毒性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Locally recurrent pancreatic cancer after prior radiotherapy is a therapeutic challenge with limited treatment options. This study examines the safety and efficacy of stereotactic body radiation therapy (SBRT) for locally recurrent pancreatic adenocarcinoma after prior conventional fractionation radiotherapy (CRT). METHODS AND MATERIALS: Outcomes from all patients treated with SBRT for locally recurrent pancreatic adenocarcinoma after prior CRT at our institution were reviewed. A total of 23 patients were identified. Prior CRT median dose was 50.4 Gy (range, 30-60 Gy). Twelve patients (52%) had previously undergone surgery and received CRT as neo- or adjuvant treatment. Nine patients (39.1%) were reirradiated with SBRT with a dose of 25 Gy in a single fraction, and 14 patients (60.8%) received a 5-fraction SBRT schedule with a median dose of 25 Gy (range, 20-33 Gy) in 5 fractions (1-5 fractions). RESULTS: Median follow-up time was 28 months (range, 9-77 months). The median planning target volume was 46 cm3 (range, 14-89 cm3). Median overall survival from diagnosis and from reirradiation were 27.5 months (range, 10-77 months) and 8.5 months (range, 1 month to not reached) respectively. The cumulative incidence of local failures at the last follow-up was 19%. For the 4 patients who presented with local failure, one was treated with a single fraction of 25 Gy, and the other 3 were treated with 25 Gy in 5 fractions. Three patients presented regional failure, with a cumulative incidence of 14%, all with concurrent distant progression. The cumulative incidence of distant progression was 64% at last follow-up. After reirradiation, 6 patients (26.1%) developed a grade 2 or 3 gastrointestinal toxicity, 4 of them occurring among patients treated with a single-fraction SBRT regimen. CONCLUSIONS: Our report shows that SBRT for reirradiation of locally recurrent pancreas adenocarcinoma is a feasible option with good local control and acceptable toxicity rates, especially with a multifraction schedule.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Koong AJ, Toesca DAS, von Eyben R, et al. Reirradiation with stereotactic body radiation therapy after prior conventional fractionation radiation for locally recurrent pancreatic adenocarcinoma. Adv Radiat Oncol. 2017. PMID: 28740913. doi:10.1016/j.adro.2017.01.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。